Transcription factors are adaptor molecules that detect regulatory sequences in the DNA
and target the assembly of protein complexes that control gene expression. Yet much of the …

Abstract Oestrogen receptor-positive (ER+) breast cancer is a major cause of cancer death
in women. Although aromatase inhibitors suppress the function of ER and reduce the risk of …

Current standard-of-care (SOC) therapy for breast cancer includes targeted therapies such
as endocrine therapy for estrogen receptor-alpha (ERα) positive; anti-HER2 monoclonal …

Estrogen receptor α (ER) is the major driver of∼ 75% of breast cancers, and multiple ER
targeting drugs are routinely used clinically to treat patients with ER+ breast cancer …

Abstract CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have shown
impressive efficacy in estrogen receptor-positive advanced breast cancer. However, most …

Estradiol (E2) regulates gene expression at the transcriptional level by functioning as a
ligand for estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). E2-inducible …

Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic
studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show …

The 15 members of the kallikrein-related serine peptidase (KLK) family have diverse tissue-
specific expression profiles and putative proteolytic functions. The kallikrein family is also …

The estrogen receptor α (ERα) controls cell proliferation and tumorigenesis by recruiting
various cofactors to estrogen response elements (EREs) to control gene transcription. A …

Despite the role of the estrogen receptor α (ERα) pathway as a key growth driver for breast
cells, the phenotypic consequence of exogenous introduction of ERα into ERα‐negative …